Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer

详细信息    查看全文

• 作者：Hassan A. Hatoum (1)
  Faek R. Jamali (2)
  Nagi S. El-Saghir (1)
  Khaled M. Musallam (1)
  Muhieddine Seoud (3)
  Hani Dimassi (4)
  Jaber Abbas (2)
  Mohamad Khalife (2)
  Fouad I. Boulos (5)
  Ayman N. Tawil (5)
  Fadi B. Geara (6)
  Ziad Salem (1)
  Achraf A. Shamseddine (1)
  Karine Al-Feghali (1)
  Ali I. Shamseddine (1)
  
• 刊名：Indian Journal of Surgical Oncology
• 出版年：2010
• 出版时间：January 2010
• 年：2010
• 卷：1
• 期：1
• 页码：68-75
• 全文大小：241KB
• 参考文献：1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, / CA Cancer J Clin. 2008;58:71-6. CrossRef
  2. Morton DL. Intra-operative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation? / Cancer J Sci Am. 1997;3:328-0.
  3. Kutiyanawala MA, Sayed M, Stotter A, et al. Staging the axilla in breast cancer: an audit of lymph-node retrieval in one UK regional centre. / Eur J Surg Oncol. 1998;24:280-. CrossRef
  4. Smeets A, Christiaens MR. Implications of the sentinel lymph node procedure for local and systemic adjuvant treatment. / Curr Opin Oncol. 2005;17:539-4. CrossRef
  5. Schulze T, Mucke J, Markwardt J, et al. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. / J Surg Oncol. 2006;93:109-9. CrossRef
  6. Woodward WA, Strom EA, Tucker SL, et al. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. / J Clin Oncol. 2003;21: 3244-. CrossRef
  7. Recht A, Gray R, Davidson NE, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. / J Clin Oncol. 1999;17:1689-00.
  8. Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. / J Clin Oncol. 2004;22:4247-4. CrossRef
  9. Vinh-Hung V, Burzykowski T, Cserni G, et al. Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. / Int J Oncol. 2003;22:697-04.
  10. Vinh-Hung V, Cserni G, Burzykowski T, et al. Effect of the number of uninvolved nodes on survival in early breast cancer. Oncol Rep. 2003;10:363-.
  11. Krag DN, Single RM. Breast cancer survival according to number of nodes removed. Ann Surg Oncol. 2003;10:1152-. CrossRef
  12. van der Wal BC, Butzelaar RM, van der Meij S, et al. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. / Eur J Surg Oncol. 2002;28: 481-. CrossRef
  13. Voordeckers M, Vinh-Hung V, Van de Steene J, et al. The lymph node ratio as prognostic factor in nodepositive breast cancer. / Radiother Oncol. 2004;70:225-0. CrossRef
  14. Vinh-Hung V, Verschraegen C, Promish DI, et al. Ratios of involved nodes in early breast cancer. / Breast Cancer Res. 2004;6:R680-. CrossRef
  15. Truong PT, Berthelet E, Lee J, et al. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. / Cancer. 2005;103:2006-3. CrossRef
  16. Kuru B. Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. / Eur J Surg Oncol. 2006;32:1082-. CrossRef
  17. Lale Atahan I, Yildiz F, Ozyigit G, et al. Percent positive axillary lymph node metastasis predicts survival in patients with nonmetastatic breast cancer. / Acta Oncol. 2008;47:232-. CrossRef
  18. Vinh-Hung V, Verkooijen HM, Fioretta G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. / J Clin Oncol. 2009;27:1062-. CrossRef
  19. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York, NY: Springer; 2002.
  20. Atkinson EN, Brown BW, Montague ED. Tumor volume, nodal status, and metastasis in breast cancer in women. / J Natl Cancer Inst. 1986; 76:171-.
  21. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. / Cancer. 1989;63:181-. CrossRef
  22. Gray RJ. Flexible methods for analyzing survival data using splines, with application to breast cancer prognosis. / J Am Stat Assoc. 1992; 87:942-1. CrossRef
  23. Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. / Breast Cancer Res Treat. 1998;52:227-7. CrossRef
  24. Sauerbrei W, Royston P, Bojar H, et al. Modelling the effects of standard prognostic factors in nodepositive breast cancer: German Breast Cancer Study Group (GBSG). / Br J Cancer. 1999;79:1752-0. CrossRef
  25. McMasters KM. The eternally enigmatic axilla: further controversy about axillary lymph node in breast cancer. / Ann Surg Oncol. 2003; 10:1128-0. CrossRef
  26. Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. / Lancet. 2005; 365:1687-7. CrossRef
  27. Early Breast Cancer Trialists-Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. / Lancet. 2005;366:2087-06.
  28. Baslaim MM, Al Malik OA, Al Sobhi SS, et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. / Am J Surg. 2002;184:299-01. CrossRef
  29. Kyndi M, S?rensen FB, Knudsen H, et al. Danish Breast Cancer Cooperative Group. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in highrisk breast cancer: the Danish Breast Cancer Cooperative Group. / J Clin Oncol. 2008;26:1419-6. CrossRef
  30. The Steering Committee on Clinical Practice. Guidelines for the care and treatment of breast cancer. / CMAJ. 1998;158(Suppl 3):S1-.
  31. Weir L, Speers C, D’Yachkova Y, et al. Prognostic significance of the number of axillary lymph nodes removed in patients with nodenegative breast cancer. / J Clin Oncol. 2002;20:1793-. CrossRef
  32. Fowble B, Solin LJ, Schultz DJ, et al. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. / Int J Radiat Oncol Biol Phys. 1989; 17:703-0.
  33. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian metaanalysis. / Ann Surg Oncol. 1999;6:109-6. CrossRef
  34. Chaudhry R, Goel V, Sawka C. Breast cancer survival by teaching status of the initial treating hospital. / CMAJ. 2001;164:183-.
  35. Sosa JA, Diener-West M, Gusev Y, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. / Ann Surg Oncol. 1998;5:140-. CrossRef
  36. Gillanders WE, Mikhitarian K, Hebert R, et al. Molecular detection of micrometastatic breast cancer in histopathologynegative axillary lymph nodes correlates with traditional predictors of prognosis: an interim analysis of a prospective multiinstitutional cohort study. / Ann Surg. 2004;239:828-7. CrossRef
  37. Cserni G, Bianchi S, Boecker W, et al. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. / Cancer. 2005; 103:358-7. CrossRef
  38. Turner RR, Weaver DL, Cserni G, et al. Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. / J Clin Oncol. 2008;26:258-3. CrossRef
  39. Sakorafas GH, Tsiotou AG, Balsiger BM. Axillary lymph node dissection in breast cancer-current status and controversies, alternative strategies and future perspectives. / Acta Oncol. 2000;39:455-6. CrossRef
  40. Bundred NJ, Morgan DA, Dixon JM. ABC of breast diseases. Management of regional nodes in breast cancer. / Br Med J. 1994;309:1222-.
  
• 作者单位：Hassan A. Hatoum (1)
  Faek R. Jamali (2)
  Nagi S. El-Saghir (1)
  Khaled M. Musallam (1)
  Muhieddine Seoud (3)
  Hani Dimassi (4)
  Jaber Abbas (2)
  Mohamad Khalife (2)
  Fouad I. Boulos (5)
  Ayman N. Tawil (5)
  Fadi B. Geara (6)
  Ziad Salem (1)
  Achraf A. Shamseddine (1)
  Karine Al-Feghali (1)
  Ali I. Shamseddine (1)
  
  1. Department of Internal Medicine, Division of Hematology/Oncology, American University of Beirut Medical Center, Beirut, Lebanon
  2. Department of Surgery, Division of General Surgery, American University of Beirut Medical Center, Beirut, Lebanon
  3. Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Beirut, Lebanon
  4. School of Pharmacy, Lebanese American University, Byblos, Lebanon
  5. Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon
  6. Department of Radiation Oncology, American University of Beirut Medical Center, Beirut, Lebanon
  

文摘

Background The status of the axillary lymph nodes in nonmetastatic lymph node-positive breast cancer (BC) patients remains the single most important determinant of overall survival (OS). Although the absolute number of nodes involved with cancer is important for prognosis, the role of the total number of excised nodes has received less emphasis. Thus, several studies have focused on the utility of the axillary lymph node ratio (ALNR) as an independent prognostic indicator of OS. However, most studies suffered from shortcomings, such as including patients who received neoadjuvant therapy or failing to consider the use of adjuvant therapy and tumor receptor status in their analysis. Methods We conducted a single-center retrospective review of 669 patients with nonmetastatic lymph nodepositive BC. Data collected included patient demographics; breast cancer risk factors; tumor size, histopathological, receptor, and lymph node status; and treatment modalities used. Patients were subdivided into four groups according to ALNR value (<0.25, 0.25-.49, 0.50-.74, 0.75-.00). Study parameters were compared at the univariate and multivariate levels for their effect on OS. Results On univariate analysis, both the absolute number of positive lymph nodes and the ALNR were significant predictors of OS. On multivariate analysis, only the ALNR remained an independent predictor of OS, with a 2.5-fold increased risk of dying at an ALNR of ?.25. Conclusions Our study demonstrates that ALNR is a stronger factor in predicting OS than the absolute number of positive axillary lymph nodes.